# Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

> **NCT00541970** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 961 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Cervarix
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00541970
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-17
- **Primary completion:** 2013-03-18
- **Final completion:** 2013-03-18
- **Target enrollment:** 961 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541970, "Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00541970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*